Arcellx raises $115M to advance controllable cell therapies

By The Science Advisory Board staff writers

April 13, 2021 -- Arcellx has raised $115 million to advance its pipeline of adaptive and controllable cell therapies.

Proceeds from the financing will support the company's development of a B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR)-modified T-cell therapy called CART-ddBCMA. The agent is currently in a phase I clinical trial for the treatment of relapsed and refractory multiple myeloma and is expected to begin a pivotal trial in 2022.

Furthermore, the funding will support the initiation of clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from the company's controllable ARC-SparX platform. This agent is targeted at the treatment of multiple myeloma and acute myelogenous leukemia, respectively.

The series C financing was co-led by Samsara BioCapital and CAM Capital.


Copyright © 2021 scienceboard.net


Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter